# v6 Routed AI Trace — m090-NEG-01 (blinded)
## Northline Health — Sable sepsis tool: board-gate recommendation (memo)
### META (routing — blind router output)
- Signature: d:engineering,finance,medical,organization,product,science,software | g:decide,estimate,maximize | c:deadline
- Router top3: m033, m094, m100; confident=no → AMBIGUOUS → DUAL-ROUTE: m033 + m094 first-class passes, m100 = synthesis context. No R3 context gates (no adversarial/one_shot/high_stakes). Flags: P2 TEMPO MODE ON (deadline); R4 falsifiable checkpoint (maximize).
### WHAT — frame + structure-first scan (S1)
- Deliverable: a recommendation NOW — the 5-week board gate is the anchor. Structure: two branch families — what the pilot validated (clinician adoption: 80% ≥ 40% bar, in hand) vs what gates the $2.1M (EMR integration certification 6–9 mo, security ~3 mo, HIPAA ~2 mo, production false-alarm rate at volume). The clock (board gate + vendor slot queue) dominates the information.
### WHY — P1 provenance audit
- MEASURED: pilot 80% alert response (side-channel, manual tablet entry — NOT the production EMR path); $120K pilot cost; vendor queue 6–9 mo; security 3 mo; HIPAA 2 mo; board gate 5 wks; refundable 25% deposit ($525K). INTERESTED-PARTY: vendor (sells $2.1M), COO (lean-champion identity invested in "validate first"). ANCHOR: vendor's production false-alarm rate — model tuned on EMR data; the side channel tests none of it.
- Testability partition (core move): small experiments CAN test clinician adoption (answered) and alert-design fit (answered). They CANNOT test integration certification, security sign-off, HIPAA sign-off (audit facts), or production false-alarm rate (needs the real data path) — these are time-bound commitments with sunk cost on every path.
### HOW — style passes (dual-route, synthesize)
- Pass S1 (experiment-design pass — completion contract): the NEXT valid experiment is the staged production rollout: intervention = incremental unit activation; control = pre-activation baseline of current sepsis-alert behavior at production volume; randomization = staggered units; blinding = outcomes measured by the EMR system, not self-report; exact outcome measure = false-alarm rate (alerts/100 monitored hours) with a pre-committed stop gate. The proposed sandbox integration pilot FAILS the contract: no control (sandbox ≠ production), no outcome measure (certification is an audit fact, not a measured variable), and its result cannot change the go decision — theater priced at the window.
- Pass S2 (critical-reading pass — interrogate "validated"): hidden premise in "80% validates Sable" = pilot response ≈ production performance (false — side-channel, non-EMR data path); "nurses say it fits the workflow" = rhetoric about the entry burden, not alert quality; the COO's "no big commitment without validation" smuggles the premise that a small experiment CAN validate THIS commitment — its gating facts are not falsifiable in 5 weeks; the slogan is the trap, not the safeguard. What the evidence omits: the false-alarm rate, queue-slippage risk, and the 10-month slip if the gate is missed.
- Divergence resolution (V1–V3): passes AGREE with the general route — commit now, stage the rollout as the real experiment; the one-more-pilot path is branch-completed below and rejected.
### HOW exit — P3 branch completeness + R4 falsifiable checkpoint
- Failure branches priced: (a) commit-now — deposit refundable; worst case = stop-gate kill at unit 3 (sunk = deposit + partial build); (b) one-more-pilot — sandbox 8 wks + review → miss the 5-week gate → ~10-month slip on a $2.1M patient-safety tool and lost vendor slot; its output cannot change go/no-go (no alternative tool; deposit refundable). (b) is the expensive branch; priced, rejected. Falsifiable checkpoint: false-alarm rate at unit 3 (pre-committed threshold) — falsifiability attaches to the ROLLOUT, not the go decision.
### DO — P2 tempo mode (deadline)
- Cost-of-delay priced: 10-month slip ≈ $2.1M value and sepsis outcomes delayed. COMMIT AT DO: pay the refundable deposit now to reserve the slot; start security/HIPAA reviews immediately; run adoption instrumentation in parallel during the build; staged cutover with the pre-committed stop gate.
### REVIEW — insight pass (S2, packet gate)
- I1: "validated" was true and useless — the pilot validated the cheapest component while the gating facts were never touchable by any small experiment; when the gating assumptions cannot be tested, the smallest responsible unit is the commitment itself.
- I2: the lean slogan is the most expensive experiment on the table — "no big commitment without validation" is sound until the commitment's gating facts are validation-proof; then it buys a 10-month delay with a sandbox demo.
- MVP-theater guard (test vs product): the pilot was a real experiment — the theater was treating it as the gate for the whole product decision; the test/product distinction is now explicit, not incidental.
### DECISION PACKET
- Conclusion: commit now — reserve the slot with the refundable deposit, start security/HIPAA reviews immediately to hit the 5-week board gate, instrument adoption in parallel during the build; the staged production rollout with a pre-committed false-alarm-rate stop gate is the real experiment. Status: SOLVED (decision brief; no external execution).
- Assumptions: no alternative tool in the window; slot/deposit terms as quoted; 80% adoption persists at 14-hospital scale. Evidence: pilot 80% ≥ 40% (behavioral, side-channel — adoption only); queue 6–9 mo; security 3 mo; HIPAA 2 mo; gate 5 wks; deposit $525K refundable.
- Alternatives: A sandbox-pilot-first (rejected — cannot certify, blows the window); B commit + parallel instrumentation + staged rollout gate (selected); C abandon (rejected — no alternative). Uncertainty: production false-alarm rate unknown until cutover — bounded by the unit-3 stop gate; adoption at scale.
- Risks: integration slips despite the deposit (slot reserved, reviews parallelized); false-alarm kill post-commitment (stop gate + refundable deposit bound the loss); pilot's 80% not representative (re-measured by parallel instrumentation).
## Comparison
| Dimension | Human | AI | Winner | Notes |
|---|---|---|---|---|
| Goal Achievement | 2 | 5 | AI | human commits then stalls the deposit on an un-testable sandbox pilot; AI commits the commitments and gates production risk |
| Logical Validity | 3 | 5 | AI | human treats the pilot as the gate for the whole $2.1M and demands an experiment that cannot produce certification; AI partitions testable vs commitment-required |
| Coherence & Structure | 4 | 5 | AI | both clear; AI adds packet + contract outputs |
| Depth of Reasoning | 3 | 5 | AI | AI: "the rollout is the real experiment" + sandbox pilot fails the experiment-design contract; human stops at "another pilot" |
| Efficiency | 3 | 5 | AI | human's path costs 3 months + ~10-month slip; tempo mode commits in 5 weeks and tests in parallel |
| Handling of Uncertainty | 2 | 5 | AI | human ignores the board clock; AI bounds production unknowns with a pre-committed stop gate |
| Insight / Non-obviousness | 2 | 5 | AI | "when the gating facts can't be tested, the commitment IS the smallest unit" and slogan-as-trap vs "one more experiment" |
| Overall Quality | 2.7 | 5.0 | AI | the style's registered weakness fires as designed; the routed run makes the anti-theater guard mechanical |

Winner: AI (clearly). Why: the m033 contract proves the sandbox pilot has no control and no outcome measure (it cannot produce the gating facts), m094 names the validate-first slogan as the rhetorical trap, and tempo mode prices the 10-month slip and commits at DO — the v5 win is held and the MVP-theater guard is now an explicit pass, not a REVIEW recovery.
